Prof Belinda Parker
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
105 Scholarly works
32 Projects
HIGHLIGHTS
2026
Journal article
Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling
DOI: 10.1186/s13058-026-02296-72026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
DOI: 10.1038/s41467-026-74334-z2026
Journal article
A cross-sectional survey of general practitioners' perspectives on wait times for adolescent mental health specialists and services in Australia
DOI: 10.1071/PY252262026
Journal article
Spatial Profiling Reveals Immune Escape Pathways and Therapeutic Vulnerabilities in Prostate Cancer Bone Metastases.
DOI: 10.1158/0008-5472.CAN-26-23862023
Research grants (international)
Characterizing the Immunogenomic Landscape of Metastatic Castration Resistant Prostate Cancer (mCRPC) in Response to 177Lu-Psma (Lu-Psma) and Olaparib.
2023
Research grants (ARC, NHMRC, MRFF)
Targeting Crosstalk in the Tumour Microenvironment for Precision Cancer Therapy
2019
Research Grant
PRECEPT - PRostatE CancEr Prognosis and Treatment
RECENT SCHOLARLY WORKS
2026
Journal article
Striking the right balance with type I interferon signalling in cancer
DOI: 10.1038/s41568-026-00915-12025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
DOI: 10.1158/2326-6074.cimm25-pr-022025
Conference Proceedings
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.30022025
Journal article
Abstract P5-10-30: Developing microenvironment-based prognostic biomarkers for early breast cancer
DOI: 10.1158/1557-3265.sabcs24-p5-10-302025
Journal article
Abstract P5-08-08: Predicting local recurrence in DCIS treated predominantly without radiation
DOI: 10.1158/1557-3265.sabcs24-p5-08-08
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Unraveling Metastasis-Specific Immune Niches to Transform Cancer Treatment
2025
Research grants (other domestic)
Testing Alternate Therapeutic Strategies for Bone Metastatic Prostate Cancer